Table 1.
Single-agent PARIS® test drug screen results.
| Drug | Target | C max | IC50 | SPM |
|---|---|---|---|---|
| Ceritinib | ALK, IGF-1R, ROS1 | 1.43E−06 | 1.10E−06 | 14 |
| Lapatinib | EGFR, HER2 | 4.04E−06 | 1.30E−06 | 13 |
| Fulvestrant | Selective estrogen receptor degrader | 2.08E−08 | NA | 12 |
| Neratinib | EGFR, HER1, HER2, HER4 | 2.14E−07 | 8.50E−08 | 12 |
| Everolimus | mTORC1 | 3.86E−08 | 7.60E−06 | 10 |
| Crizotinib | ALK, ROS1, MET | 9.48E−07 | 5.60E−06 | 9 |
| Enzalutamide | Androgen receptor antagonist | 3.57E−05 | 1.00E−05 | 9 |
A list of the drugs that indicated sensitivity according to the PARIS® test was ranked using the SPM score as single drugs. Drug name, gene product target, and maximal serum observed dose (Cmax) as obtained from the literature; all drugs included are FDA-approved. SPM, SEngine Precision Medicine.